Article

Coverage Recap: ONS 37th Annual Congress

Author(s):

A recap of our coverage from the Oncology Nursing Society 37th Annual Congress, in New Orleans, where thousands of oncology nurses gathered and shared valuable clinical insights.

This past weekend, thousands of oncology nurses gathered in New Orleans for the Oncology Nursing Society (ONS) 37th Annual Congress. Nurses from across the country traveled to “The Big Easy” to network and share valuable clinical insights. Here is a recap of our coverage:

Oncology Nursing Society Elects New President

At this year’s conference, Mary Gullatte, PhD, RN, APRN, BC, AOCN, associate chief nursing officer at Emory Healthcare’s Crawford Long Hospital, Atlanta, Georgia, officially took over as the new ONS president. Gullatte spoke with us just before the conference to talk about the importance of addressing challenges in the workplace—from a potential oncology nursing shortage to finding ways to improve infrastructure—and determining how to address the potential challenges of the future before they have a chance to become problematic.

Oncology Nurses Need to Enhance Their Genetics and Genomics Competency

While genetics and genomics have become an important part of understanding the development and progression of cancer, research has shown that many nurses have a limited knowledge of this field. Georgie Cusack, MS, RN, AOCNS®, and Jean Jenkins, PhD, RN, FAAN, from the National Institutes of Health, discussed the resources that nurses can take advantage of to bring them up to speed in their respective practices.

Talking to Prostate Cancer Patients About Sipuleucel-T: Nurses Assure Smooth Sailing During Treatment

Sipuleucel-T (Provenge) has caused excitement after promising studies showed improved survival in patients with metastatic castration-resistant prostate cancer. Allison Tyler, RN, BSN, OCN, CCRP, clinical research nurse at the Cleveland Clinic, discussed how nurses play a vital role in providing patients with the education and care associated with this revolutionary new treatment option.

Oncology Nurses Can Help Mitigate Treatment-Related Side Effects in Head & Neck Cancers

Patients treated for head and neck cancer often experience a number of side effects that can impact a patient’s well-being during and after treatment. Jean Holland, MSN, RN, AOCN, Clinical Nurse of Radiation Oncology at Fox Chase Cancer Center in Philadelphia, discussed how nurses can monitor these patients and help manage these troubling side effects.

Treating Patients Enrolled in Clinical Trials

Oncology nurses in clinical practice settings are increasingly expected to be able to handle the needs of patients enrolled in clinical trials. Denise Friesema, MS, RN, OCN, University of Chicago Medical Center, Illinois, discussed the importance of documentation, following protocol, and monitoring progress during these trials.

Identifying Appropriate Patients for HER2-Targeted Therapies

HER2-targeted therapies are promising agents for patients with HER2-positive breast cancer, a form of the disease often associated with poorer outcomes. Kristine Abueg, RN, MSN, OCN®, Kaiser Permanente, Roseville, California, discussed testing for HER2 and the criteria associated with eligibility for HER2 targeted therapies.

ASCO/ONS Chemotherapy Safety Standards Updated to Include All Delivery Settings

While the majority of patients receiving chemotherapy are adult outpatients, this does not necessarily reflect all patients receiving chemotherapy. Martha Polovich, PhD, RN, AOCN, Oncology Clinical Nurse Specialist at Duke Oncology Network, Durham, North Carolina, discussed the updated ASCO/ONS Chemotherapy Safety Standards, which now reflect the proper method of delivering chemotherapy to patients in all delivery settings.

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie